Chateauroux

This research aims to evaluate the real-life effectiveness, safety, usage, tolerance, and satisfaction of four CE-marked isotonic and hypertonic seawater-based nasal sprays. It focuses on infants, children, adults, and pregnant or breastfeeding women who suffer from acute and chronic sinonasal conditions such as upper respiratory tract infections, COVID-19, bronchiolitis, allergic rhinitis, chronic rhinosinusitis, and post-surgery recovery. The study seeks to answer key questions on how well these nasal sprays work and how safe and satisfactory they are in everyday use. Participants will use one of four nasal sprays designed for different age groups and indications. The sprays are applied by spraying 1 to 3 seconds into each nostril multiple times daily, depending on the product and condition. Treatment for nasal symptoms ranges from 2 to 6 times a day, while hygiene and prevention uses are less frequent. The nasal sprays are used according to their intended purpose and population, including special instructions for babies, children, and adults. During the study, participants or their parents/caregivers will perform nasal washes following healthcare provider advice and complete online questionnaires about their symptoms and experience. Researchers will monitor nasal symptom improvement over 5 days for acute conditions and up to 14 days for chronic conditions. The study includes assessments of nasal symptom intensity, nasal breathing impairment, safety, and user satisfaction. Participants are expected to comply with study requirements for up to 3 months and have daily internet access for questionnaire completion.

Researchers are studying the safety and effectiveness of the Dexter Robotic System for patients undergoing robotic-assisted right colectomy, a surgical procedure on the colon. The purpose is to confirm how well this robotic system performs during and shortly after surgery, focusing on both safety and clinical outcomes. Participants will receive a right colectomy using the Dexter robotic surgery system. This device assists surgeons during the operation. The study will monitor patients through the perioperative period and up to 30 days after surgery to assess the safety and performance of the robotic system. During the study, participants will be followed for 30 days after surgery, with assessments following the standard of care. Researchers will measure safety outcomes within this period and evaluate the effectiveness of the procedure during the operation itself. Patient follow-up is important to understand the early postoperative effects and overall clinical performance of the device.

Researchers are conducting an ambispective, observational, multicenter, and multicohort study focusing on patients with non-small cell lung cancer (NSCLC) who are starting treatment with approved drugs developed by AstraZeneca (AZ) or as part of an AZ alliance. The study includes three groups based on NSCLC stage: resectable, unresectable, and metastatic. This modular study design allows assessment of each new drug indication once it receives European marketing authorization and becomes available in the participating countries. Patients will be enrolled if they have received, are receiving, or will receive approved AZ or AZ alliance drugs either alone or in combination, at any disease stage. Treatment decisions are made by the patients' own doctors before joining the study. The study follows these patients in three cohorts: resectable NSCLC, unresectable NSCLC, and metastatic NSCLC, to evaluate outcomes related to drug effectiveness in real-world settings. Participants will be followed for up to three years to measure outcomes such as disease-free survival, event-free survival, and time to treatment failure, depending on their cohort. Data collection includes retrospective and prospective information on treatment start and patient progress. The study emphasizes real-world evidence by observing patients receiving standard care without intervention from the study team.